PharmaSeq

Home Company News & Events Press Releases 2012 National Cancer Institute Contracts with PharmaSeq for Prostate Cancer Assay Development

Press Releases

National Cancer Institute Contracts with PharmaSeq for Prostate Cancer Assay Development

Monmouth Junction, NJ, October 11, 2012. PharmaSeq, Inc., announced today the receipt of a Phase I Contract from the National Cancer Institute titled "Multiplex Prostate Cancer Serum Assay on RFID p-Chips".

The contract is aimed at the development of an efficient, cost effective, serum-based multiplex assay using PharmaSeq's p-Chip platform for early detection of clinically significant prostate cancer. The panel, which will include combining antibodies to several protein biomarkers along with prostate-specific antigen (PSA), is being developed to improve the clinical specificity of prostate cancer detection without compromising the high sensitivity of PSA testing alone. Currently, no single biomarker can fulfill the clinical needs of both high sensitivity and specificity. The work will be performed at PharmaSeq and through a subcontract with the Fisher Biomarker & Biorepository Laboratory (FBBL) at the Johns Hopkins University School of Medicine in Baltimore, MD.

The goal of the study is to evaluate whether combining additional biomarkers can improve the ability to discriminate clinically significant prostate cancer from indolent states when the test results are united with total PSA. The current project addresses a new dilemma that exists in prostate cancer care: choosing between costly procedures often perceived as overdiagnosis and overtreatment that do lead to a reduced mortality due to prostate cancer, but also to undesired side effects, pain and suffering, or advising against routine prostate cancer screening, with consequences of not identifying early clinically significant forms of prostate cancer. The national debate has been recently stirred up by a report from the U.S. Preventive Services Task Force convened by the U.S. Agency for Healthcare Research and Quality.

Dr. Richard G. Morris, CEO of PharmaSeq, Inc., said: "this award underlines the importance of our p-Chips platform to construct highly flexible, sensitive low multiplex assays that can be deployed for both diagnostic and prognostic testing of cancers. We anticipate that this work, which follows earlier progress at both PharmaSeq and the Johns Hopkins School of Medicine in this area, will eventually reduce the overall costs borne by our healthcare system by eliminating hundreds of thousands of prostate biopsies due to false positives from PSA testing alone".

For further information, please contact Dr. Richard G. Morris, CEO, or Dr. Wlodek Mandecki, President, at (732) 355-0100 ext 11.

PharmaSeq, Inc.
11 Deer Park Drive, Suite 104
Monmouth Junction, NJ 08852


Find us on the web at: www.pharmaseq.com.


Download as PDF

Home Company News & Events Press Releases 2012 National Cancer Institute Contracts with PharmaSeq for Prostate Cancer Assay Development